- Home
- NRC vs SLN Comparison
NRC vs SLN Comparison
Compare NRC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- SLN
- Stock Information
- Founded
- NRC 1981
- SLN 1994
- Country
- NRC United States
- SLN United Kingdom
- Employees
- NRC N/A
- SLN N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- SLN Health Care
- Exchange
- NRC Nasdaq
- SLN Nasdaq
- Market Cap
- NRC 354.5M
- SLN 299.4M
- IPO Year
- NRC N/A
- SLN N/A
- Fundamental
- Price
- NRC $14.65
- SLN $4.81
- Analyst Decision
- NRC
- SLN Buy
- Analyst Count
- NRC 0
- SLN 5
- Target Price
- NRC N/A
- SLN $32.60
- AVG Volume (30 Days)
- NRC 101.8K
- SLN 61.8K
- Earning Date
- NRC 10-24-2025
- SLN 08-07-2025
- Dividend Yield
- NRC 3.27%
- SLN N/A
- EPS Growth
- NRC N/A
- SLN N/A
- EPS
- NRC 0.77
- SLN N/A
- Revenue
- NRC $140,314,000.00
- SLN $27,169,000.00
- Revenue This Year
- NRC N/A
- SLN N/A
- Revenue Next Year
- NRC N/A
- SLN N/A
- P/E Ratio
- NRC $19.08
- SLN N/A
- Revenue Growth
- NRC N/A
- SLN 22.28
- 52 Week Low
- NRC $9.76
- SLN $1.97
- 52 Week High
- NRC $22.99
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- NRC 47.80
- SLN 34.88
- Support Level
- NRC $14.45
- SLN $4.91
- Resistance Level
- NRC $15.60
- SLN $5.34
- Average True Range (ATR)
- NRC 0.64
- SLN 0.48
- MACD
- NRC -0.03
- SLN -0.05
- Stochastic Oscillator
- NRC 17.05
- SLN 0.71
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.